Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity

Keywords

Weight loss and diet.

Outcome Measures

Primary Outcomes (1)

Weight

Secondary Outcomes (1)

Waist and hip circumference

Interventions

Metformin and Metformin + FenofibrateDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Metformin and Metformin + Fenofibrate
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age30 Years - 50 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Both genders, BMI ≥ 30 kg/m² and \<40 kg/m².

You may not qualify if:

Sponsors & Collaborators

Solvay Pharmaceuticals
Industrylead

Study Sites (3)

Site 1

Helsinki, Finland

Site 3

Kuopio, Finland

Site 2

Oulu, Finland

MeSH Terms

Conditions

ObesityWeight Loss

Interventions

MetforminFenofibrate

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsBody Weight Changes

Intervention Hierarchy (Ancestors)

Biguanides

Study Officials

Global Clinical Director Solvay
Solvay Pharmaceuticals
STUDY DIRECTOR

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: DOUBLE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

July 6, 2006

First Posted

July 7, 2006

Study Start

October 2004

Date type not reported

This date has not been verified as actual or estimated.

Last Updated

September 3, 2007

Record last verified: 2007-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00349635
Data provider: ClinicalTrials.gov
Source updated: 2007-09-03
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:21 UTC

A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations